TransCode Therapeutics (NASDAQ:RNAZ) Announces Completion of $8 Million Private Placement

TransCode Therapeutics, a biopharmaceutical company specializing in RNA therapeutics for cancer treatment, disclosed on November 26, 2024, the completion of a significant private placement. The company entered into a securities purchase agreement with accredited investors, resulting in the sale of an aggregate of 5,710,000 shares of common stock, 15,510,160 pre-funded warrants, and 21,220,160 Series C […]

Leave a Reply

Your email address will not be published.

Previous post Trial of Brian Walshe, accused of killing and dismembering Cohasset wife, set for October 2025
Next post Great Portland Estates (OTCMKTS:GPEAF) Sets New 12-Month Low – Time to Sell?